Skip to main content
SpringerLink
Log in

ß-Rezeptorenblocker

  • Chapter
Herzkrankheiten

  • 242 Accesses

Zusammenfassung

ß-Rezeptorenblocker sind charakterisiert durch ihren Isoprenalinantagonismus. Sie hemmen dosisabhängig die Wirkung des spezifischen synthetischen ß-Stimulators Isoprenalin durch reversible Bindung an ß-Rezeptoren. Ebenso werden die über ß-Rezeptoren vermittelten Wirkungen der biologischen adrenergen Überträgersubstanzen Adrenalin und Noradrenalin gehemmt. Daraus sind Wirkprofil, maximal erreichbare Wirkung und eine charakteristische Dosiswirkungskurve der ß-Rezeptorenblocker ableitbar. Therapeutische Wirkungen basieren auf der Hemmung einer pathogen wirksamen endogenen ß-Stimulation, unerwünschte Nebenwirkungen dagegen auf der Hemmung einer notwendigen ß-Stimulation — je nach Diagnose und klinischer Situation. Mit der Strukturaufklärung der humanen ß1, ß2- und ß3-Rezeptoren und der Feststellung erheblicher Unterschiede ist eine weitere Zentrierung auf diese ß-Rezeptorsubtypen in Grundlagenforschung und Therapie noch nicht abgeschlossen.

Der nachfolgende Beitrag beschränkt sich auf die allgemeine Pharmakologie dieser Substanzen. Ihr therapeutischer Einsatz bei bestimmten Indikationen wird in den speziellen Kapiteln abgehandelt.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 299.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 379.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Ahlquist RP (1948) A study of the adrenotropic receptors. Am J Physiol 153:586

    PubMed  CAS  Google Scholar 

  • Arstall MA, Hii JTY, Lehman RG, Horowitz JD (1992) Sotalolinduced torsade de pointes: management with magnesium infusion. Postgrad Med J 68:289–290

    Article  PubMed  CAS  Google Scholar 

  • Black JW, Crowther AF, Shanks RG et al (1964) New adrenergic beta-receptor antagonist. Lancet 1:1080–1081

    Article  PubMed  CAS  Google Scholar 

  • Black JW, Stephenson JS (1962) Pharmacology of a new adrenergic ßreceptor blocking compound (nethalide). Lancet 11:311

    Article  Google Scholar 

  • Buckley MMT, Grant SM, Goa KL et al (1990) Diltiazem. Drugs 39:757–806

    Article  PubMed  CAS  Google Scholar 

  • Cheymol G, Poirier J-M, Carrupt P-A et al (1997a) Pharmacokinetics of ßadrenoceptor blockers in obese and normal volunteers. Br J Clin Pharmacol 43:563–570

    Article  PubMed  CAS  Google Scholar 

  • Cheymol G, Woestenborghs R, Snoeck E et al (1997b) Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. Eur J Clin Pharmacol 51:493–498

    Article  PubMed  CAS  Google Scholar 

  • Clark DWJ (1985) Genetically determined variability in acetylation and oxidation. Drugs 29:342–375

    Article  PubMed  CAS  Google Scholar 

  • Conolly ME, Kersting F, Dollery CT (1976) The clinical pharmacology of beta-adrenoceptor blocking drugs. Progr cardiovasc Dis 19:203

    Article  CAS  Google Scholar 

  • Daaka Y, Luttrell LM, Lefkowitz RJ (1997) Switching of the coupling of the ß2-adrenergic receptor to different G-proteins by protein kinase. Nature 390:88–91

    Article  PubMed  CAS  Google Scholar 

  • Dale HH (1906) On some physiological actions of ergot. J Physiol Lond 34:163

    PubMed  Google Scholar 

  • Davies PH, Franklyn JA (1991) The effects of drugs on tests of thyreoid function. Eur J Clin Pharmacol 40:439–451

    Article  PubMed  CAS  Google Scholar 

  • Deedwania PC (1990) Suppressant effects of conventional betablockers and Sotalol on complex and repetitive ventricular premature complexes. Am J Cardiol 65:43A–52A

    Article  PubMed  CAS  Google Scholar 

  • Detroyer A, Vander Heyden Y, Carda-Broch S et al (2001) Quantitative structure-retention and retention-activity relationships of ß-blocking agents by micellar liquid chromatography. J Chromatograph A 912:211–221

    Article  CAS  Google Scholar 

  • Dhein S, Titzer S, Wallstein M et al (1992) Celiprolol exerts microvascular dilatation by activation of ß2-adrenoceptors. Naunyn-Schmiedeberg’s Arch Pharmacol 346:27–31

    Article  CAS  Google Scholar 

  • Dornhorst A, Powell SH, Pensky J (1985) Aggravation by Propranolol of hyperglycaemic effect of hydrochlorothiazide in type 2 diabetics without alteration of insulin secretion. Lancet 1:123–126

    Article  PubMed  CAS  Google Scholar 

  • Du Souich P, Verges J, Erill S (1993) Plasma protein binding and pharmacological response. Clin Pharmacokin 24:435–440

    Article  Google Scholar 

  • Farmer JB, Kennedy I, Levy GP, Marshall RJ (1972) Pharmacology of AH 5158, a drug which blocks both alpha-und beta-adrenoceptors. Br J Pharmacol 45:660–675

    Article  PubMed  CAS  Google Scholar 

  • Feely J, Peden N (1984) Use of ß-adrenoceptor blocking drugs in hyperthyroidism. Drugs 27:425–446

    Article  PubMed  CAS  Google Scholar 

  • Fitton A, Sorkin EM (1993) Sotalol. An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias. Drugs 46:678–719

    Article  PubMed  CAS  Google Scholar 

  • Frielle T, Collins S, Daniel KW et al (1987) Cloning of the cDNA for the ß1 adrenergic receptor. Proc Natl Acad Sci USA 84:7920–7924

    Article  PubMed  CAS  Google Scholar 

  • Harbarth ST (1993) Dosisabhängigkeit der ß-stimulierenden Eigenwirkung des ß-Rezeptorenblockers Carteolol. Inaugural Dissertation München

    Google Scholar 

  • Hemeryck A, Lefebvre RA, de Vriendt C et al (2000) Paroxetine affects metoprolol pharmacokinetics and pharmocodynamics in healthy volunteers. Clin. Pharmacol Ther 67:283–291

    Article  PubMed  CAS  Google Scholar 

  • Hoffmann BB, Taylor T (2001) Neurotransmission: The autonomic and somatic motor nervous systems, pp 115-153. In: Hardman JG, Limbird LE, Gilman AG (eds) The pharmacological basis of therapeutics, 10th ed. McGraw-Hill,New Y

    Google Scholar 

  • Ishizaki T, Privitera PJ, Walle Th, Gaffney ThE (1974) Cardio-vascular actions of a new metabolite of propranolol: isopropylamine. J Pharmacol exp Ther 189:626–632

    PubMed  CAS  Google Scholar 

  • Jacobs H, Brandt U, Farkas P, Frishman W (1983) Beta-adrenergic blockade and the gastrointestinal system. Am J Med 74:1042–1051

    Article  Google Scholar 

  • Johnsson G, Regardh CG (1976) Clinical pharmacokinetics of ß-adrenoceptor blocking drugs. Clin Pharmacokin 1:233

    Article  CAS  Google Scholar 

  • Julian DG, Prescott RJ, Jackson FS, Szekely P (1982) Controlled trial of sotalol for one year after myocardial infarction. Lancet 1:1142–1147

    Article  PubMed  CAS  Google Scholar 

  • Juul-Möller S, Edvardsson N, Rehnqvist-Ahlberg N (1990) Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 82:1932–1939

    Article  PubMed  Google Scholar 

  • Kaumann AJ, Blinks JB (1980) ß-Adrenoceptor blocking agents as partial agonists in isolated heart muscle: dissociation of stimulation and blockade. Naunyn-Schmiedeberg’s Arch Pharmacol 311:237–248

    Article  CAS  Google Scholar 

  • Kaumann AJ, Olson CB (1968) Temporal relation between longlasting aftercontractions and action potentials in cat papillary muscles. Science 161:293–295

    Article  PubMed  CAS  Google Scholar 

  • Kostis JB, Rosen RC (1987) Central nervous system effects of ß-adrenergic blocking drugs: the role of ancillary properties. Circulation 75:204–212

    Article  PubMed  CAS  Google Scholar 

  • Krapf R, Gertsch M (1985) Torsade de pointes induced by sotalol despite therapeutic plasma sotalol concentrations. Br Med J 290:1784–1785

    Article  CAS  Google Scholar 

  • Lands AM, Arnold A, McAuliff JP et al (1967) Differentiation of receptor systems activated by sympathomimetic amines. Nature 214:597

    Article  PubMed  CAS  Google Scholar 

  • Langley JN (1905) Ort the reaction of cells and of nerve endings to certain poisons chiefly as regards the reaction of striated muscle to nicotine and to curare. J Physiol Lond 33:374

    PubMed  Google Scholar 

  • Lefkowitz RJ (1973) Isolated beta-adrenergic binding sites: A potential assay vehicle for catecholamines. Pharmacol Rev 5:259

    Google Scholar 

  • Lohmann FW (1981) Die Beeinflussung des Stoffwechsels durch ß-Rezeptorenblocker? Klin Wochenschr 59:49–57

    Article  PubMed  CAS  Google Scholar 

  • Lohmöller G (1992) Schützt die ß1-Selektivität von Betaxolol-Augentropfen vor Bronchialobstruktion. Klin Wochenschr 69 (Suppl):23:17

    Google Scholar 

  • Lohmöller G, Lydtin H, Fröhlich ED (1976) Antihypertensive und hämodynamische Wirkungen von ß-Rezeptorenblockern mit unterschiedlichen Wirkungsspektren. Advanc Clin Pharmacol 11:94–98

    Google Scholar 

  • Lohmöller G, Lydtin H (1996) ß-Rezeptorenblocker. In: Roskamm H, Reindell H (Hrsg) Herzkrankheiten, 4. Aufl., S 1278–1300. Springer, Berlin Heidelberg New York

    Chapter  Google Scholar 

  • Lohmöller G, Middeke M, Mrowka Ch et al (1989) Klinische Bedeutung der ISA des ß-Blockers Carteolol. Teil II: Vergleichende Untersuchungen von Carteolol und Pindolol bei Patienten mit Bradykardie. Med Klin 84:81–85

    Google Scholar 

  • Lydtin H (1977) Side effects of contraindications of ß-receptor blocking agents. Klin Wochenschr 55:485

    Article  Google Scholar 

  • Lydtin H, Lohmöller G (1977) ß-Rezeptorenblocker. Aesopus, Lugano München

    Google Scholar 

  • Lydtin H, Lohmöller G, Daniel W et al (1971) Kardiovaskuläre Wirkungen von Glukagon vor und nach Propranololgabe. Verh Dtsch Ges Inn Med 77:1000–1004

    PubMed  CAS  Google Scholar 

  • Mason JW (1993) A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. New Engl J Med 329:452–458

    Article  PubMed  CAS  Google Scholar 

  • Monopoli A, Forlani A, Bevilacqua M et al (1989) Interaction of selected vasodilating ß-blockers with adrenergic receptors in human cardiovascular tissues. J Cardiovasc Pharmacol 14:114–120

    Article  PubMed  CAS  Google Scholar 

  • Motulsky HJ, Insel PA (1982) Adrenergic receptors in man-direct identification, physiologic regulation, and clinical alterations. New Engl J Med 307:18–29

    Article  PubMed  CAS  Google Scholar 

  • Nattel S, Feder-Elituv R, Matthews C et al (1989) Concentration dependence of class III and beta-adrenergic blocking effects of Sotalol in anesthetized dogs. J Am Coll Cardiol 13:1190–1194

    Article  PubMed  CAS  Google Scholar 

  • Neugebauer G, Gabor M, Reiff K (1992) Disposition of Carvedilol enantiomers in patients with liver-cirrhoses. Evidence for disappearance of stereoselective first pass extraction. J Cardiovasc Pharmacol 19:S142–146

    Article  Google Scholar 

  • Neuvonen PJ, Elonen E, Tarssanen L (1979) Sotalolintoxication, two pts with concentration-effect relationship. Acta Pharmacol Toxicol 45: 52–57

    Article  CAS  Google Scholar 

  • Peer A van, Snoeck E, Woestenborghs R et al (1991) Clinical pharamcokinetics of nebivolol. A Review. Drug Invest 3(Suppl 1):25–30

    Article  Google Scholar 

  • Powell CE, Slater IH (1958) Blocking of inhibitory adrenergic receptors by a dichloranalogue of isoproterenol. J Pharmacol expTher 122:480

    CAS  Google Scholar 

  • Recanatini M (1992) Partition and distribution coefficients of aryloxypropanolamine ß-adrenoceptor antagonists. J Pharm Pharmacol 44:68–70

    Article  PubMed  CAS  Google Scholar 

  • Rees MR, Clark RA, Norldsworth CD et al (1980) The effect of ß-adrenoreceptors agonists and antagonists on gastric emptying in man. Br J din Pharmacol 10:551–554

    Article  CAS  Google Scholar 

  • Reichenberger HJ (1974) Fahrverhalten und Kreislaufreaktion am Fahrsimulator unter dem Einfluss von Practolol, Diazepam und Plazebo. Inauguraldissertation, München

    Google Scholar 

  • Salpeter SR, Ormiston TM, Salpeter EE (2002). Cardioselective ß-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med 137:715–725

    PubMed  CAS  Google Scholar 

  • Samek L, Stürzenhofecker P, Roskamm H (1980) Pindolol bei Herzinfarkt-Patienten. Münch med Wochenschr 122:1071–1074

    CAS  Google Scholar 

  • Schofield PM, Reid F, Benneit DH (1987) A comparison of atenolol and sotalol in the treatment of patients with paroxysmal supraventricular tachycardia. Br Heart J 57:105–106

    Google Scholar 

  • Senges J, Lengfelder W, Jauernig R et al (1982) Comparative effects of sotalol, metoprolol and quinidine on sustained ventricular tachycardia. Circulation 66(11):142

    Google Scholar 

  • Shanks RG (1991) Clinical pharmacology of vasodilatory ß-blocking drugs. Am Heart J 121:1006–1011

    Article  PubMed  CAS  Google Scholar 

  • Singh BN, Vaughan Williams EM (1970) A third class of antiarrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474. Br J Pharmacol 39:675–687

    Article  PubMed  CAS  Google Scholar 

  • Smith C, Teitler M (1999): Beta-blocker selectivity at cloned human beta1-and beta2-adrenergic receptors. Cardiovasc Drugs Ther 13:123–126

    Article  PubMed  CAS  Google Scholar 

  • Steinberg SF, Brunton LL (2001): Compartmentation of G protein-coupled signaling pathways in cardiac myocytes. Annu Rev Pharmacol Toxicol 41:751–773

    Article  PubMed  CAS  Google Scholar 

  • Strosberg AD (1997) Structure and function of the ß3-adrenergic receptor. Annu Rev Pharmacol Toxicol 37:421–450

    Article  PubMed  CAS  Google Scholar 

  • Suttorp MJ, Kingma JH, Gin MTJ et al (1990) Efficacy and safety of low-and high-dose Sotalol versus propranolol in the prevention of supraventricular tachyarrhythmias early after coronary artery bypass operations. J Thorac Cardiovasc Surg 100:921–926

    PubMed  CAS  Google Scholar 

  • Taillard-Bertschinger A, Martinet CAM, Carrupt P-A et al (2002) Molecular factors influencing retention on immobilized artificial membranes (IAM) compared to partitioning in liposomes and n-octanol. Pharmaceut Res 19:729–737

    Article  Google Scholar 

  • Thorpe JAC (1980) Effect of propranolol on the lower oesophageal sphincter in man. Curr Med Res Opin 7:91–94

    Article  PubMed  CAS  Google Scholar 

  • Waal-Manning HJ (1976) Metabolic effects of ß-adrenoreceptor blockers. Drugs 11, Suppl 1:121–126

    Article  PubMed  Google Scholar 

  • Wagner F, Kalusche D, Trenk D et al (1986) Kumulation von Metoprolol im Plasma unter der Therapie mit Propafenon. Z Kardiol 75:8, A66

    Google Scholar 

  • Wagner J, Schümann HH (1970) Untersuchungen über die ß-adrenolytische Wirkung sowie den Einfluß auf Refraktärzeit und Kontraktilität von INPEA und MJ 1999 am Meerschweinchenvorhof. Experientia 26:163–164

    Article  PubMed  CAS  Google Scholar 

  • Waldo AL, Camm AJ, deRuyter H et al for the SWORD Investigators (1996) Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 348:7–12

    Article  PubMed  CAS  Google Scholar 

  • Wang T, Bergstrand RH, Thompson KA et al (1986) Concentration-dependent pharmacologic properties of Sotalol. Am J Cardiol 57:1160–1165

    Article  PubMed  CAS  Google Scholar 

  • Ward DE, Camm AJ, Spurrell FAJ (1979) The acute cardiac electrophysiological effects of intravenous sotalol hydrochloride. Clin Cardiol 2:185–191

    PubMed  CAS  Google Scholar 

  • Wellstein A, Palm D, Pitschner HF, Belz GG (1985) Receptor binding of Propranolol is the missing link between plasma concentration kinetics and the effect time course in man. Eur J din Pharmacol 29:131–147

    Article  CAS  Google Scholar 

  • Werdan K, Reithmann Ch (1988) „Pseudoselektivität“ der ISA — Konsequenzen für die Differentialtherapie mit ß2-Blockern mit und ohne ISA? Dtsch med Wschr 113:272–274

    PubMed  CAS  Google Scholar 

  • Westaby D, Bihary DJ, Gimson AES et al (1984) Selective and non-selective ß-receptor blockade in the reduction of portal pressure in patients with cirrhosis and portal hypertension. Gut 25:121–124

    Article  PubMed  CAS  Google Scholar 

  • Wilcox RG (1978) Randomised study of six ß-Blockers and a thiazide diuretic in essential hypertension. Br med J 2:383–385

    Article  PubMed  CAS  Google Scholar 

  • Yorkston NJ, Zaki SA, Themen JFA, Havard CWH (1976) Safeguards in the treatment of schizophrenia with propranolol. Postgrad med J 52 (Suppl 4):175–180

    PubMed  Google Scholar 

  • Yoshida F, Topliss JG (1997) Unified model for the corneal permeability of related and diverse compounds with respect to their physicochemical properties. J Pharmaceut Sci 85:819–823

    Article  Google Scholar 

Download references

Authors
  1. G. Lohmöller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Lydtin
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Herz-Zentrum Bad Krozingen, Südring 15, 79188, Bad Krozingen, Germany

    H. Roskamm , F.-J. Neumann , D. Kalusche  & H.-P. Bestehorn , ,  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Lohmöller, G., Lydtin, H. (2004). ß-Rezeptorenblocker. In: Roskamm, H., Neumann, FJ., Kalusche, D., Bestehorn, HP. (eds) Herzkrankheiten. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18649-3_41

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-18649-3_41

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-62220-5

  • Online ISBN: 978-3-642-18649-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation